会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 76. 发明申请
    • COLONIC DELIVERY OF ANTIMICROBIAL AGENTS
    • 抗菌药物的殖民地交付
    • WO2009037264A3
    • 2009-10-29
    • PCT/EP2008062317
    • 2008-09-16
    • DA VOLTERRAANDREMONT ANTOINEDE GUNZBURG JEAN
    • ANDREMONT ANTOINEDE GUNZBURG JEAN
    • A61K38/00A61K9/14A61K9/50A61K38/43A61K39/00A61P1/00A61P31/00
    • A61K9/1652A61K9/2846A61K9/5026A61K9/5073A61K31/7036A61K38/12A61K45/06A61K2300/00
    • Antimicrobial compositions for oral delivery, and administration to the colon, distal ileum, or other portion of the gastrointestinal tract other than the stomach, of bacteriophage, phage proteins, antimicrobial peptides, or antimicrobial aptamers, are disclosed. In one embodiment, the active agent is capable of lysing the bacterial cell wall. In another embodiment, the active agent is capable of interacting with a receptor or enzyme in the bacteria. In some embodiments, the active agents selectively act on one or more harmful bacteria, such as Clostridium dificile, and either do not act, or act to a lesser extent, on helpful bacteria, such as bifidobacteria. When the agents are not delivered directly to the colon, they active agents ultimately enter the colon and affect the bacteria that are present in the colon. The compositions can include beads of pectin in the form of a cationic salt enclosing the active agent, or other types of drug delivery systems designed for targeted delivery to the desired portion of the gastrointestinal tract.
    • 公开了用于口服递送的抗微生物组合物,以及对结肠,回肠末端或除了胃之外的胃肠道的其它部分,噬菌体,噬菌体蛋白,抗微生物肽或抗微生物适体体的给药。 在一个实施方案中,活性剂能够裂解细菌细胞壁。 在另一个实施方案中,活性剂能够与细菌中的受体或酶相互作用。 在一些实施方案中,活性剂选择性地作用于一种或多种有害细菌,例如梭菌(Clostridium dificile),并且不会对有用的细菌例如双歧杆菌起作用或在较小程度上起作用。 当试剂不直接递送到结肠时,它们的活性剂最终进入结肠并影响结肠中存在的细菌。 组合物可以包括呈封闭活性剂的阳离子盐形式的果胶珠或设计用于靶向递送至胃肠道所需部分的其它类型的药物递送系统。
    • 78. 发明申请
    • COLONIC DELIVERY OF ANTIMICROBIAL AGENTS
    • 结肠给药的抗微生物剂
    • WO2009037264A2
    • 2009-03-26
    • PCT/EP2008/062317
    • 2008-09-16
    • DA VOLTERRAANDREMONT, AntoineDE GUNZBURG, Jean
    • ANDREMONT, AntoineDE GUNZBURG, Jean
    • A61K38/00A61K38/43A61K39/00A61K9/14A61K9/50A61P1/00A61P31/00
    • A61K9/1652A61K9/2846A61K9/5026A61K9/5073A61K31/7036A61K38/12A61K45/06A61K2300/00
    • Antimicrobial compositions for oral delivery, and administration to the colon, distal ileum, or other portion of the gastrointestinal tract other than the stomach, of bacteriophage, phage proteins, antimicrobial peptides, or antimicrobial aptamers, are disclosed. In one embodiment, the active agent is capable of lysing the bacterial cell wall. In another embodiment, the active agent is capable of interacting with a receptor or enzyme in the bacteria. In some embodiments, the active agents selectively act on one or more harmful bacteria, such as Clostridium dificile , and either do not act, or act to a lesser extent, on helpful bacteria, such as bifidobacteria. When the agents are not delivered directly to the colon, they active agents ultimately enter the colon and affect the bacteria that are present in the colon. The compositions can include beads of pectin in the form of a cationic salt enclosing the active agent, or other types of drug delivery systems designed for targeted delivery to the desired portion of the gastrointestinal tract.
    • 用于经口递送以及施用于结肠,远端回肠或除胃以外的胃肠道的其他部分的噬菌体,噬菌体蛋白质,抗微生物肽或抗微生物适体的抗微生物组合物被公开 。 在一个实施方案中,活性剂能够溶解细菌细胞壁。 在另一个实施方案中,活性剂能够与细菌中的受体或酶相互作用。 在一些实施方案中,活性剂选择性地作用于一种或多种有害细菌,例如梭菌,并且对有益细菌如双歧杆菌不起作用或在较小程度上起作用。 当药物不直接递送到结肠时,它们的活性剂最终进入结肠并影响存在于结肠中的细菌。 所述组合物可以包括以封闭活性剂的阳离子盐形式的果胶珠,或设计用于靶向递送至胃肠道期望部分的其他类型的药物递送系统。